NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.
최신 재무제표(Form-10K)에 따르면, NewcelX AG의 총 자산은 $0이며, 순손실입니다.
NCEL의 주요 재무 비율은 무엇인가요?
NewcelX AG의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
NewcelX AG의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
NewcelX AG 주요 수익원은 Conversational Artificial Intelligence Technology이며, 최신 수익 발표에서 수익은 256,384입니다. 지역별로는 United States이 NewcelX AG의 주요 시장이며, 수익은 256,384입니다.